Veeva Systems Posts Best Day Ever as Q2 Beat and Vault CRM Wins Drive 17% Stock Surge

Veeva Systems shares surged as much as 20.9% on August 27, closing up roughly 15-17% in what Barron's called the stock's best single day ever, after the life sciences software company reported fiscal second-quarter 2027 results that beat expectations on every metric. Adjusted earnings per share came in at $2.35, well above the consensus estimate of $2.22, while subscription revenues rose 16% year-over-year to $766.8 million and total revenue grew 18%, the highest growth rate in nine quarters. Management raised the full-year fiscal 2027 adjusted EPS outlook to $9.21 from $9.05, and guided third-quarter adjusted EPS of $2.33 to $2.34, topping the prior consensus of $2.28.

A key driver was accelerating momentum for Vault CRM, Veeva's next-generation replacement for its legacy Salesforce-based system. More than 180 customers are now live on Vault CRM, including five top-20 biopharma companies, and total top-20 commitments reached 12 globally. In August alone, two additional top-20 biopharmas and one large enterprise biopharma committed to the platform.

Named wins cited by analysts included Eli Lilly, Biogen, and Regeneron. CFO Brian Van Wagener said results exceeded guidance on all metrics and that the company's full-year view improved across the board. Multiple Wall Street firms raised their price targets in response, including Needham, Jefferies, Stifel, Truist, Piper Sandler, and TD Cowen, citing the CRM wins and strong execution.

Year to date through the day of the report, Veeva shares were up roughly 29%.